Akari Therapeutics Partners with WuXi XDC to Advance PH1 Payload Development

Akari Therapeutics has announced a strategic collaboration with WuXi XDC to accelerate the development of its novel PH1 payload technology. The partnership aims to leverage WuXi XDC’s antibody-drug conjugate (ADC) development capabilities to enhance preclinical and clinical progression of Akari’s next-generation therapeutic pipeline.

Strengthening ADC Development Capabilities

The collaboration is expected to combine Akari’s innovative payload design with WuXi XDC’s integrated ADC discovery, development, and manufacturing platform. This synergy is likely to streamline development timelines while improving the efficiency of payload optimization for targeted therapies.

Expanding Global Biopharma Innovation Strategy

This partnership reflects the growing trend of cross-border collaborations in the biopharmaceutical sector, particularly in oncology-focused ADC programs. By aligning with WuXi XDC, Akari strengthens its global development strategy and positions its PH1 payload platform for broader clinical and commercial advancement.